Posted by Michael Wonder on 18 Dec 2024
Health Canada approves Xeomin (incobotulinumtoxinA) for treatment of adults with post-stroke lower limb spasticity in the ankle and foot
17 December 2024 - Merz Therapeutics today announced that Health Canada approved Xeomin (incobotulinumtoxinA) for the treatment of post-stroke lower limb spasticity involving the ankle and foot in adults.
Canada is the third country to authorise Xeomin for lower limb treatment based on data from a Japanese study (J-PLUS), which investigated the effects of Xeomin on spasticity in Japanese stroke survivors.
